Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stromal cell therapy (R.P. Herrmann)
- Development stage
- Unknown
- Lead developer
- Royal Perth Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Mesenchymal stromal cell therapy (R.P. Herrmann) is an investigational cell-based biologic therapy developed by R.P. Herrmann at Royal Perth Hospital for the treatment of acute graft-versus-host disease (GVHD). The therapy consists of allogeneic, third-party, bone marrow-derived mesenchymal stromal cells (MSCs) administered intravenously. These MSCs exert immunomodulatory effects by suppressing T-cell proliferation, inducing regulatory T-cells, and releasing various immunomodulatory factors to mitigate the inflammatory response associated with GVHD. It has been evaluated in Phase 2 clinical trials as an adjunct to standard corticosteroid treatment for patients with newly diagnosed (de novo) grades 2-4 acute GVHD following allogeneic bone marrow transplantation.
- Other names
- allogeneic human mesenchymal stromal cellsbone marrow-derived mesenchymal stromal cellsMSC therapy (R.P. Herrmann)
Beyond the preview
Go deeper on mesenchymal stromal cell therapy (R.P. Herrmann).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stromal cell therapy (R.P. Herrmann).